A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.

NCT Number	NCT07222670
Lead Sponsor	ENA Respiratory Pty Ltd
Conditions	Viral Respiratory Infection, Viral Respiratory Illnesses
Enrollment	1,100 participants
Start Date	2025-12-04
Primary Completion	2027-02-09 (estimated)
Study Completion	2027-02-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-11